High‐throughput identification of conditional MHCI ligands and scaled‐up production of conditional MHCI complexes

Despite the need to monitor the impact of Cancer Immunotherapy (CI)/Immuno‐Oncology (IO) therapeutics on neoantigen‐specific T‐cell responses, very few clinical programs incorporate this aspect of immune monitoring due to the challenges in high‐throughput (HTP) generation of MHCI tetramers across a wide range of HLA alleles. This publication develops a novel workflow to enable identification and validation of conditional MHCI ligands across a range of HLA alleles.

Darwish, M., Wichner, S., et al. Protein Science 2021. https://doi.org/10.1002/pro.4082